Equities Analysts Offer Predictions for Esperion Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Zacks Research lowered their Q1 2025 EPS estimates for Esperion Therapeutics in a research note issued on Tuesday, October 8th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.02) EPS.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to analyst estimates of $51.90 million.

ESPR has been the subject of a number of other reports. Bank of America cut Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, October 2nd. Needham & Company LLC reduced their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Finally, StockNews.com raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, October 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Stock Up 4.2 %

ESPR stock opened at $1.97 on Friday. The company has a market cap of $386.57 million, a P/E ratio of -2.29 and a beta of 1.00. The business has a fifty day moving average of $1.82 and a 200-day moving average of $2.19. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40.

Institutional Trading of Esperion Therapeutics

Several large investors have recently made changes to their positions in the company. Bellevue Group AG lifted its holdings in shares of Esperion Therapeutics by 136.5% in the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after acquiring an additional 5,739,800 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Esperion Therapeutics by 2.7% during the 1st quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock worth $24,467,000 after buying an additional 238,544 shares during the period. Vanguard Group Inc. increased its stake in Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after purchasing an additional 3,688,796 shares in the last quarter. Marshall Wace LLP raised its stake in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after buying an additional 2,087,635 shares during the period. Finally, GSA Capital Partners LLP raised its position in shares of Esperion Therapeutics by 1.0% during the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock worth $3,373,000 after purchasing an additional 11,494 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.